Updated: Novo Nordisk’s semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

No­vo Nordisk’s semaglu­tide in­jec­tion re­duced ma­jor ad­verse car­dio­vas­cu­lar events by 20% in obese or over­weight pa­tients with­out di­a­betes, fur­ther bol­ster­ing the case for more wide­spread use of the game-chang­ing GLP-1.

No­vo Nordisk said Tues­day morn­ing that the vast SE­LECT tri­al in­ves­ti­gat­ing semaglu­tide hit its pri­ma­ry end­point: the re­duc­tion in ma­jor ad­verse car­dio­vas­cu­lar events (MACE), which in­cludes car­dio­vas­cu­lar death, non-fa­tal my­ocar­dial in­farc­tion or non-fa­tal stroke, com­pared with place­bo. It en­rolled 17,604 adults who were 45 years or old­er, over­weight or obese, and had a di­ag­no­sis of car­dio­vas­cu­lar dis­ease. There were 1,270 first MACEs in the study, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.